Philadelphia Trust Company’s AstraZeneca AZN Stock Holding History

Philadelphia Trust Company’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$493K	Hold	2,498	–	–	0.03%	161
2025 Q4	$459K	Buy	2,498 +655	+36%	+$115K	0.03%	165
2025 Q3	$283K	Hold	1,843	–	–	0.02%	206
2025 Q2	$258K	Hold	1,843	–	–	0.02%	209
2025 Q1	$271K	Hold	1,843	–	–	0.02%	207
2024 Q4	$242K	Hold	1,843	–	–	0.02%	214
2024 Q3	$287K	Sell	1,843 -106	-5%	-$17.1K	0.02%	206
2024 Q2	$304K	Hold	1,949	–	–	0.02%	180
2024 Q1	$264K	Hold	1,949	–	–	0.02%	197
2023 Q4	$263K	Hold	1,949	–	–	0.02%	190
2023 Q3	$264K	Hold	1,949	–	–	0.03%	187
2023 Q2	$279K	Hold	1,949	–	–	0.03%	191
2023 Q1	$271K	Hold	1,949	–	–	0.03%	192
2022 Q4	$264K	Sell	1,949 -2,124	-52%	-$266K	0.03%	192
2022 Q3	$447K	Hold	4,073	–	–	0.05%	150
2022 Q2	$538K	Hold	4,073	–	–	0.06%	144
2022 Q1	$540K	Hold	4,073	–	–	0.04%	157
2021 Q4	$475K	Hold	4,073	–	–	0.03%	176
2021 Q3	$489K	Buy	+4,073	New	+$474K	0.04%	171

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Philadelphia Trust Company's AZN Position: Q1 2026 in Review

Philadelphia Trust Company held its AstraZeneca (AZN) position steady in Q1 2026 at 2,498 shares worth $493K. The position accounts for 0.03% of the portfolio, ranked #161.

Philadelphia Trust Company first reported a position in AZN in Q3 2021 and has held it in 19 quarters since. The position peaked at $540K in Q1 2022. 1,378 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Philadelphia Trust Company held 2,498 shares of AstraZeneca worth $493K as of Q1 2026.
Philadelphia Trust Company left its AstraZeneca share count unchanged in Q1 2026.
AstraZeneca made up 0.03% of Philadelphia Trust Company's portfolio in Q1 2026, its #161 holding.
Philadelphia Trust Company first reported a position in AstraZeneca in Q3 2021 and has held it in 19 quarters since.
Philadelphia Trust Company's AstraZeneca position peaked at $540K in Q1 2022.
1,378 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Philadelphia Trust Company's 13F filing for Q1 2026, filed 13 May 2026.